On May 2, 2022, Abbott Laboratories announced that at its annual general meeting of shareholder held on April 29, 2022, the shareholders rejected a shareholder proposal that Abbott's Board of Directors prepare a report on the public health costs and financial market impacts of Abbott's standards and programs regarding antimicrobial resistance.